vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and RAMBUS INC (RMBS). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $180.2M, roughly 1.1× RAMBUS INC). RAMBUS INC runs the higher net margin — 33.2% vs 12.0%, a 21.2% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 8.1%). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 16.8%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Rambus Inc. is an American technology company that designs, develops and licenses chip interface technologies and architectures that are used in digital electronics products. The company, founded in 1990, is well known for inventing RDRAM and for its intellectual property-based litigation following the introduction of DDR-SDRAM memory.

CORT vs RMBS — Head-to-Head

Bigger by revenue
CORT
CORT
1.1× larger
CORT
$202.1M
$180.2M
RMBS
Growing faster (revenue YoY)
CORT
CORT
+3.0% gap
CORT
11.1%
8.1%
RMBS
Higher net margin
RMBS
RMBS
21.2% more per $
RMBS
33.2%
12.0%
CORT
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
16.8%
RMBS

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CORT
CORT
RMBS
RMBS
Revenue
$202.1M
$180.2M
Net Profit
$24.3M
$59.9M
Gross Margin
98.7%
79.7%
Operating Margin
2.2%
34.3%
Net Margin
12.0%
33.2%
Revenue YoY
11.1%
8.1%
Net Profit YoY
-21.0%
-7.3%
EPS (diluted)
$0.20
$0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
RMBS
RMBS
Q1 26
$180.2M
Q4 25
$202.1M
$190.2M
Q3 25
$207.6M
$178.5M
Q2 25
$194.4M
$172.2M
Q1 25
$157.2M
$166.7M
Q4 24
$181.9M
$161.1M
Q3 24
$182.5M
$145.5M
Q2 24
$163.8M
$132.1M
Net Profit
CORT
CORT
RMBS
RMBS
Q1 26
$59.9M
Q4 25
$24.3M
$63.8M
Q3 25
$19.7M
$48.4M
Q2 25
$35.1M
$57.9M
Q1 25
$20.5M
$60.3M
Q4 24
$30.7M
$62.2M
Q3 24
$47.2M
$48.7M
Q2 24
$35.5M
$36.1M
Gross Margin
CORT
CORT
RMBS
RMBS
Q1 26
79.7%
Q4 25
98.7%
78.9%
Q3 25
97.8%
79.5%
Q2 25
98.2%
79.8%
Q1 25
98.5%
80.3%
Q4 24
98.4%
80.4%
Q3 24
98.4%
80.7%
Q2 24
98.5%
79.7%
Operating Margin
CORT
CORT
RMBS
RMBS
Q1 26
34.3%
Q4 25
2.2%
37.2%
Q3 25
4.9%
35.4%
Q2 25
13.7%
36.6%
Q1 25
2.2%
37.9%
Q4 24
13.9%
35.9%
Q3 24
25.5%
37.6%
Q2 24
21.7%
30.5%
Net Margin
CORT
CORT
RMBS
RMBS
Q1 26
33.2%
Q4 25
12.0%
33.6%
Q3 25
9.5%
27.1%
Q2 25
18.1%
33.6%
Q1 25
13.1%
36.2%
Q4 24
16.9%
38.6%
Q3 24
25.9%
33.4%
Q2 24
21.7%
27.3%
EPS (diluted)
CORT
CORT
RMBS
RMBS
Q1 26
$0.55
Q4 25
$0.20
$0.58
Q3 25
$0.16
$0.44
Q2 25
$0.29
$0.53
Q1 25
$0.17
$0.56
Q4 24
$0.25
$0.57
Q3 24
$0.41
$0.45
Q2 24
$0.32
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
RMBS
RMBS
Cash + ST InvestmentsLiquidity on hand
$372.2M
$134.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$647.8M
Total Assets
$836.7M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
RMBS
RMBS
Q1 26
$134.3M
Q4 25
$372.2M
$182.8M
Q3 25
$421.7M
$79.2M
Q2 25
$342.2M
$87.8M
Q1 25
$322.8M
$132.2M
Q4 24
$383.3M
$99.8M
Q3 24
$380.3M
$114.0M
Q2 24
$473.2M
$124.6M
Stockholders' Equity
CORT
CORT
RMBS
RMBS
Q1 26
Q4 25
$647.8M
$1.4B
Q3 25
$631.9M
$1.3B
Q2 25
$635.8M
$1.2B
Q1 25
$683.3M
$1.2B
Q4 24
$679.6M
$1.1B
Q3 24
$638.8M
$1.0B
Q2 24
$596.2M
$1.0B
Total Assets
CORT
CORT
RMBS
RMBS
Q1 26
$1.5B
Q4 25
$836.7M
$1.5B
Q3 25
$823.6M
$1.4B
Q2 25
$801.7M
$1.5B
Q1 25
$846.5M
$1.4B
Q4 24
$840.6M
$1.3B
Q3 24
$784.3M
$1.3B
Q2 24
$714.6M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
RMBS
RMBS
Operating Cash FlowLast quarter
$38.4M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
19.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
RMBS
RMBS
Q1 26
Q4 25
$38.4M
$99.8M
Q3 25
$54.5M
$88.4M
Q2 25
$43.9M
$94.4M
Q1 25
$5.1M
$77.4M
Q4 24
$59.3M
$59.0M
Q3 24
$73.8M
$62.1M
Q2 24
$41.2M
$70.4M
Free Cash Flow
CORT
CORT
RMBS
RMBS
Q1 26
Q4 25
$38.4M
$93.3M
Q3 25
$82.5M
Q2 25
$43.9M
$87.9M
Q1 25
$5.0M
$69.5M
Q4 24
$59.2M
$52.5M
Q3 24
$72.2M
$52.2M
Q2 24
$40.8M
$59.1M
FCF Margin
CORT
CORT
RMBS
RMBS
Q1 26
Q4 25
19.0%
49.0%
Q3 25
46.2%
Q2 25
22.6%
51.0%
Q1 25
3.2%
41.7%
Q4 24
32.5%
32.6%
Q3 24
39.5%
35.9%
Q2 24
24.9%
44.7%
Capex Intensity
CORT
CORT
RMBS
RMBS
Q1 26
Q4 25
0.0%
3.4%
Q3 25
0.0%
3.3%
Q2 25
0.0%
3.8%
Q1 25
0.1%
4.7%
Q4 24
0.1%
4.0%
Q3 24
0.9%
6.8%
Q2 24
0.3%
8.6%
Cash Conversion
CORT
CORT
RMBS
RMBS
Q1 26
Q4 25
1.58×
1.56×
Q3 25
2.77×
1.83×
Q2 25
1.25×
1.63×
Q1 25
0.25×
1.28×
Q4 24
1.93×
0.95×
Q3 24
1.56×
1.28×
Q2 24
1.16×
1.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CORT
CORT

Segment breakdown not available.

RMBS
RMBS

Product revenue$88.0M49%
Royalties$69.6M39%
Contract and other revenue$22.6M13%

Related Comparisons